Newspaper publication of financial results for the quarter/ three months ended 30/06/2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech Ltd published its unaudited standalone financial results for the quarter ended 30 June 2025 in Business Standard (English and Hindi editions) on 15 August 2025, in compliance with SEBI Listing Regulations. The company reported total income from operations of Rs. 568.86 lakhs for Q1 FY26, up sharply from Rs. 406.41 lakhs in the preceding quarter (Q4 FY25). The company swung back to profitability with a net profit of Rs. 23.60 lakhs in Q1 FY26, compared to a net loss of Rs. 52.81 lakhs in Q4 FY25. For the full FY25, total income stood at Rs. 1,355.83 lakhs with a net loss of Rs. 179.81 lakhs. The results were reviewed by the Audit Committee and approved by the Board on 13 August 2025; the company operates only in the pharmaceuticals segment.
This is a routine newspaper publication of already-filed quarterly results, not new information. The Q1 FY26 numbers indicate a sequential recovery with higher revenue and a return to profit, which is mildly positive for shareholders.